pp 1–2 | Cite as

Antagonistic effect between tigecycline and meropenem: from bed to bench to bed

  • Lavinia Arend
  • João Paulo Telles
  • Felipe Francisco TuonEmail author


Compliance with ethical standards

Conflict of interest

Felipe Tuon has received research grants from Pfizer and MSD in the last year. Felipe Tuon conducts research for CNPQ.


  1. 1.
    Bi S, Yao X, Huang C, et al. Antagonistic effect between tigecycline and meropenem: successful management of KPC-producing Klebsiella pneumoniae infection. Infection. 2019;47:497–500.CrossRefGoogle Scholar
  2. 2.
    Tuon FF, Graf ME, Merlini A, et al. Risk factors for mortality in patients with ventilator-associated pneumonia caused by carbapenem-resistant Enterobacteriaceae. Braz J Infect Dis. 2017;21:1–6CrossRefGoogle Scholar
  3. 3.
    Toledo PV, Aranha Junior AA, Arend LN, Ribeiro V, Zavascki AP, Tuon FF. Activity of antimicrobial combinations against KPC-2-producing Klebsiella pneumoniae in a rat model and time-kill assay. Antimicrob Agents Chemother. 2015;59:4301–4.CrossRefGoogle Scholar
  4. 4.
    Toledo PV, Tuon FF, Arend L, Aranha Junior AA. Efficacy of tigecycline, polymyxin, gentamicin, meropenem and associations in experimental Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae non-lethal sepsis. Braz J Infect Dis. 2014;18:574–5.CrossRefGoogle Scholar
  5. 5.
    Stein C, Makarewicz O, Bohnert JA, et al. Three dimensional checkerboard synergy analysis of colistin, meropenem, tigecycline against multidrug-resistant clinical Klebsiella pneumonia isolates. PLoS One. 2015;10:e0126479.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Laboratory of Emerging Infectious Diseases, School of MedicinePontifícia Universidade Católica do ParanáCuritibaBrazil
  2. 2.Laboratório Central do Estado (LACEN-PR)CuritibaBrazil
  3. 3.Infectious Diseases DepartmentAC Camargo Cancer CenterSão PauloBrazil

Personalised recommendations